1A01200
USP
Rosuvastatin Impurity D
Pharmaceutical Analytical Impurity (PAI)
别名:
N-[4-(4-fluorophenyl)-5-[(E)-2-[(2S,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethenyl]-6-(1-methylethyl)pyrimidin-2-yl]-N-methylmethanesulfonamide
等级
pharmaceutical analytical impurity (PAI)
Agency
USP
API类
rosuvastatin
制造商/商品名称
USP
应用
pharmaceutical
包装形式
neat
储存温度
2-8°C
SMILES字符串
Fc1ccc(cc1)c2nc(nc(c2\C=C\[C@H]3OC(=O)C[C@@H](C3)O)C(C)C)N([S](=O)(=O)C)C
InChI
1S/C22H26FN3O5S/c1-13(2)20-18(10-9-17-11-16(27)12-19(28)31-17)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)32(4,29)30/h5-10,13,16-17,27H,11-12H2,1-4H3/b10-9+/t16-,17-/m1/s1
InChI key
SOEGVMSNJOCVHT-VEUZHWNKSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
Rosuvastatin Impurity D is a USP Pharmaceutical Analytical Impurity (PAI).
USP PAI are a product line of impurities suitable for research and analytical purposes, which help to ensure the quality and safety of medicines.
Associated Drug Substance: Rosuvastatin Calcium
Therapeutic Area: Antihyperlipidemics
For more information about this PAI, visit here.
USP PAI are a product line of impurities suitable for research and analytical purposes, which help to ensure the quality and safety of medicines.
Associated Drug Substance: Rosuvastatin Calcium
Therapeutic Area: Antihyperlipidemics
For more information about this PAI, visit here.
应用
Rosuvastatin Impurity D (USP PAI) is intended for use in analytical testing to detect, identify, and measure pharmaceutical impurities.
特点和优势
USP PAI advance your early analytical R&D and process development. PAI can be used in the following applications:
1. Conduct analytical tests during early formulation feasibility studies.
2. Determine degradation impurities produced during stress studies.
3. Develop, validate, and transfer analytical methods.
4. Perform spiking studies during process R&D to demonstrate depletion upon recrystallization.
5. Record retention times and/or spectra
6. Determine relative response factors.
7. Identify unknown impurities that formed during ICH stability conditions.
8. Identify impurities that are present in the Reference Listed Drug
9. Test for and profile impurities not listed in drug substance and drug product monographs.
1. Conduct analytical tests during early formulation feasibility studies.
2. Determine degradation impurities produced during stress studies.
3. Develop, validate, and transfer analytical methods.
4. Perform spiking studies during process R&D to demonstrate depletion upon recrystallization.
5. Record retention times and/or spectra
6. Determine relative response factors.
7. Identify unknown impurities that formed during ICH stability conditions.
8. Identify impurities that are present in the Reference Listed Drug
9. Test for and profile impurities not listed in drug substance and drug product monographs.
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
警示用语：
Warning
危险声明
预防措施声明
危险分类
STOT RE 2 Oral
靶器官
Liver,Kidney
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
此项目有
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持